Preliminary studies of differential impairments of the dopaminergic system in subtypes of progressive supranuclear palsy

Lin, Wen−Piao; Lin, Kun‐Ju; Weng, Yi-Hsin; Yen, Tzu‐Chen; Shen, Lie-Hang; Liao, Mei-Hsiu; Lu, Chin‐Song

doi:10.1097/mnm.0b013e32833e5f90

Cited by 22 publications

(21 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies of ( 99m Tc)‐TRODAT‐1 have also shown significantly reduced striatal uptake in PD compared to non‐degenerative causes of Parkinsonism, such as essential tremor, vascular Parkinsonism and drug‐induced Parkinsonism . However, PD cannot be reliably distinguished from atypical Parkinsonian syndromes (which are also characterised by dopaminergic degeneration), such as multiple system atrophy, corticobasal degeneration and progressive supranuclear palsy . Case 2 was consistent with this evidence, with asymmetrically decreased tracer uptake in the left putamen (Fig.…”

Section: Discussionsupporting

confidence: 55%

Clinical utility of (^99mTc)‐TRODAT‐1 scans to differentiate Parkinsonian syndromes: case studies and commentary

Wong

Veitch

Schembri

2018

Internal Medicine Journal

View full text Add to dashboard Cite

The differential diagnosis of Parkinsonian syndromes is challenging, especially in the elderly as they often have complex presentations. Nuclear imaging modalities can increase diagnostic accuracy. Single-photon emission tomography (SPECT) using the ligand ( Tc)-TRODAT-1 is used overseas but is yet to be approved in Australia. Three pilot cases of clinically unclear Parkinsonian syndromes from the Royal North Shore Hospital Aged Care Department who underwent ( Tc)-TRODAT-1 scans are described. From experience overseas, the ( Tc)-TRODAT-1 scan has clinical utility in the differential diagnosis of Parkinsonian syndromes. ( Tc)-TRODAT-1 has a lower cost and greater availability than other ligands. Our initial scan findings are largely consistent with the clinical picture, but low specific binding can affect scan interpretation. ( Tc)-TRODAT-1 is a potential tool in the differential diagnosis of Parkinsonian syndromes. Further experience regarding its effect on patient outcomes and cost effectiveness is required before routine clinical use can be recommended.

show abstract

Section: Discussionsupporting

confidence: 55%

Clinical utility of (^99mTc)‐TRODAT‐1 scans to differentiate Parkinsonian syndromes: case studies and commentary

Wong

Veitch

Schembri

2018

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…Nevertheless, the dopamine D 2 receptor imaging is successfully demonstrated in differentiation of the subtypes of progressive supranuclear palsy: Richardson's syndrome (RS) and progressive supranuclear palsy-parkinsonism (PSP-P). Assessment of pre- and postsynaptic dopaminergic activities in Richardson's syndrome, PSP-P, or idiopathic Parkinson's disease with 99m Tc-TRODAT-1 and 123 I-IBZM images showed that the activities of D 2 receptor were reduced in Richardson's syndrome but not in PSP-P ( P < 0.01), which was consistent with the clinical manifestation of PSP-P group with better prognosis and levodopa responsiveness than that of RS patients [55]. …”

Section: Parkinson's Disease and Other Movement Disordersmentioning

confidence: 64%

Recent Advances in Imaging of Dopaminergic Neurons for Evaluation of Neuropsychiatric Disorders

Shen

Liao

Tseng

2012

Journal of Biomedicine and Biotechnology

Self Cite

View full text Add to dashboard Cite

Dopamine is the most intensely studied monoaminergic neurotransmitter. Dopaminergic neurotransmission plays an important role in regulating several aspects of basic brain function, including motor, behavior, motivation, and working memory. To date, there are numerous positron emission tomography (PET) and single photon emission computed tomography (SPECT) radiotracers available for targeting different steps in the process of dopaminergic neurotransmission, which permits us to quantify dopaminergic activity in the living human brain. Degeneration of the nigrostriatal dopamine system causes Parkinson's disease (PD) and related Parkinsonism. Dopamine is the neurotransmitter that has been classically associated with the reinforcing effects of drug abuse. Abnormalities within the dopamine system in the brain are involved in the pathophysiology of attention deficit hyperactivity disorder (ADHD). Dopamine receptors play an important role in schizophrenia and the effect of neuroleptics is through blockage of dopamine D2 receptors. This review will concentrate on the radiotracers that have been developed for imaging dopaminergic neurons, describe the clinical aspects in the assessment of neuropsychiatric disorders, and suggest future directions in the diagnosis and management of such disorders.

show abstract

“…Brain stem DAT levels could differentiate PSP‐RS and MSA from PD with 89.7% sensitivity and 94.1% specificity in 1 study . Little is currently known about the diagnostic utility of DAT findings in vPSP, although there is evidence from a few studies that both PSP‐PGF and PSP‐P are associated with striatal DAT reductions similar to those in PSP‐RS, with similar putamen‐to‐caudate ratios …”

Section: Pet/spectmentioning

confidence: 87%

Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

et al. 2017

View full text Add to dashboard Cite

PSP is a pathologically defined neurodegenerative tauopathy with a variety of clinical presentations including typical Richardson's syndrome and other variant PSP syndromes. A large body of neuroimaging research has been conducted over the past two decades, with many studies proposing different structural MRI and molecular PET/SPECT biomarkers for PSP. These include measures of brainstem, cortical and striatal atrophy, diffusion weighted and diffusion tensor imaging abnormalities, [18F] fluorodeoxyglucose PET hypometabolism, reductions in striatal dopamine imaging and, most recently, PET imaging with ligands that bind to tau. Our aim was to critically evaluate the degree to which structural and molecular neuroimaging metrics fulfill criteria for diagnostic biomarkers of PSP. We queried the PubMed, Cochrane, Medline, and PSYCInfo databases for original research articles published in English over the past 20 years using postmortem diagnosis or the NINDS-SPSP criteria as the diagnostic standard from 1996 to 2016. We define a five-level theoretical construct for the utility of neuroimaging biomarkers in PSP, with level 1 representing group-level findings, level 2 representing biomarkers with demonstrable individual-level diagnostic utility, level 3 representing biomarkers for early disease, level 4 representing surrogate biomarkers of PSP pathology, and level 5 representing definitive PSP biomarkers of PSP pathology. We discuss the degree to which each of the currently available biomarkers fit into this theoretical construct, consider the role of biomarkers in the diagnosis of Richardson's syndrome, variant PSP syndromes and autopsy confirmed PSP, and emphasize current shortfalls in the field.

show abstract

Preliminary studies of differential impairments of the dopaminergic system in subtypes of progressive supranuclear palsy

Abstract: The studies showed different alterations of DAT and D2 receptor function between the RS and PSP-P groups. Different DAT imaging might be helpful to distinguish PSP-P from PD in the early stage.

Cited by 22 publications

References 22 publications

Clinical utility of (^99mTc)‐TRODAT‐1 scans to differentiate Parkinsonian syndromes: case studies and commentary

Clinical utility of (^99mTc)‐TRODAT‐1 scans to differentiate Parkinsonian syndromes: case studies and commentary

Recent Advances in Imaging of Dopaminergic Neurons for Evaluation of Neuropsychiatric Disorders

Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

Contact Info

Product

Resources

About

Preliminary studies of differential impairments of the dopaminergic system in subtypes of progressive supranuclear palsy

Abstract: The studies showed different alterations of DAT and D2 receptor function between the RS and PSP-P groups. Different DAT imaging might be helpful to distinguish PSP-P from PD in the early stage.

Cited by 22 publications

References 22 publications

Clinical utility of (99mTc)‐TRODAT‐1 scans to differentiate Parkinsonian syndromes: case studies and commentary

Clinical utility of (99mTc)‐TRODAT‐1 scans to differentiate Parkinsonian syndromes: case studies and commentary

Recent Advances in Imaging of Dopaminergic Neurons for Evaluation of Neuropsychiatric Disorders

Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

Contact Info

Product

Resources

About

Clinical utility of (^99mTc)‐TRODAT‐1 scans to differentiate Parkinsonian syndromes: case studies and commentary

Clinical utility of (^99mTc)‐TRODAT‐1 scans to differentiate Parkinsonian syndromes: case studies and commentary